Payers may see biosims as a no-brainer, but marketing them won't be
13 December 2016
Spurring demand for biosimilars may become the new pharma marketing challenge in 2017, even as biosimilar launches accelerate in the U.S.
Sweden joins dash to host EU drugs agency instead of London after Brexit
13 December 2016
The Swedish government on Thursday launched a campaign to become the new host of the London-based European drugs agency after Britain's vote to leave the European Union and compete with offers from other EU members including Spain, France and Poland.
Drug pricing remains the big issue for 2017; Let’s not go down the rabbit hole at the FDA
12 December 2016
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Analysts on amyloid thesis: It's not dead yet
12 December 2016
Just a few weeks back, many were writing off the amyloid hypothesis in Alzheimer’s after Lilly posted top-line data showing its candidate failed a phase 3. Last night, however, Biogen released some fresh data for its drug aducanumab that, alongside some more detailed info from Lilly’s failed med, may just warrant another look.
Study: IBM Watson agrees with cancer docs on treatment options 90% of the time
12 December 2016
Since it launched its Watson Health unit last spring, IBM has rolled out cognitive computing tools for a number of applications, including genomics and oncology. But while the Jeopardy-winning supercomputer has generated a lot of buzz, critics are still wondering: is Watson really useful in these areas?
Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
09 December 2016
Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discount.
Editing set to broaden genetic blood fixes
09 December 2016
Fixing genetic diseases such as hemophilia, sickle-cell disease, and certain immunodeficiencies at their root, by replacing or repairing the faulty gene, has gone from dream to drug, with two gene therapies now approved in Europe, and a number of additional approvals expected on both sides of the Atlantic over the next few years.
On a scale of 1-10: Earth gets a 3 for infectious disease readiness
09 December 2016
Tuberculosis, malaria, pandemic flu and an unknown disease are among the scariest infectious disease threats according to a group of experts gathered in Qatar for a global health summit. And, on a scale of one to 10, the state of readiness of the world to deal with such an outbreak was a resounding three.
China is narrowing the U.S. lead in cancer research
08 December 2016
Chinese researchers are publishing more than three times as many research papers on cancer topics than they were a decade ago, closing the gap with their U.S. counterparts. China now has more than 17% of the global share of cancer research publications, up from around 5% in the mid-2000s, and now matches the output of the U.S. in 2005, according to a just-published report from science publisher Elsevier.
Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
07 December 2016
Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discount.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024